Retatrutide is a once-weekly injection that mimics three hormones involved in appetite, blood sugar, and how the body uses energy: GLP-1: lowers appetite and blood sugar GIP: lowers appetite and blood sugar Glucagon: increases energy expenditure and the breakdown of stored fat, including fat in the liver The glucagon component is what separates retatrutide from semaglutide, which mimics one hormone (GLP-1), and tirzepatide, which mimics two (GLP-1 and GIP)
* Promover una prdida de peso significativa en personas con obesidad o sobrepeso con al menos una comorbilidad relacionada con el peso
Areas of decreased cellularity (Antoni B) adjacent to areas of increased cellularity (Antoni A) 2
Product Features 11mg PT-141 peptide per vial Lyophilised powder format Research grade material Sealed laboratory vial Tamper-evident cap Individually batch coded For laboratory research use only Product Specification Storage Instructions Store refrigerated between 2C and 8C Keep vial sealed until use Protect from heat, moisture, and direct sunlight Handle only within suitable laboratory conditions Important Notice This product is supplied strictly for laboratory research and analytical purposes only
Tirzepatide in Clinical Trials Comparing safety head-to-head shows both medications have similar tolerability profiles, though tirzepatide's dual GLP-1/GIP action may cause slightly higher gastrointestinal effects at initiation
E., Anderson, J
